Premium
Association of onabotulinum toxin A treatment with salivary pH and dental caries of neurologically impaired children with sialorrhea
Author(s) -
Ferraz dos Santos Beatriz,
Dabbagh Basma,
Daniel Sam J,
Schwartz Stephane
Publication year - 2016
Publication title -
international journal of paediatric dentistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.183
H-Index - 62
eISSN - 1365-263X
pISSN - 0960-7439
DOI - 10.1111/ipd.12156
Subject(s) - sialorrhea , medicine , saliva , oral hygiene , logistic regression , dentistry , oral health , case control study , gastroenterology , anesthesia
Background Sialorrhea is a common manifestation of several neurological disorders. The use of intraglandular onabotulinum toxin A ( OBTXA ) injection has been recognized to effectively treat sialorrhea. As OBTXA injection reduces salivary flow rate and alters salivary quality, its use may have a detrimental effect on oral health. Aim To examine the effect of OBTXA injection on caries experience and salivary pH of neurologically impaired children with sialorrhea. Design Twenty‐five children receiving OBTXA treatment and 25 control children were enrolled in the study. Whole saliva was collected to determine salivary pH . All participants underwent an interview on their dietary habits. Dental clinical examinations were carried out to evaluate caries experience and oral hygiene level. Results Overall, mean salivary pH value was significantly lower in the OBTXA group (6.92 ± 0.77) compared with the control group (7.36 ± 0.70). Caries activity was significantly higher in the OBTXA group ( P = 0.01). The regression analyses showed a significant association between OBTXA treatment and salivary pH value ( P = 0.03). Results from the logistic regression show that dental caries was significantly associated with OBTXA treatment ( OR = 1.73, CI = 1.14–27.3). Conclusions The study showed an intricate relationship between OBTXA treatment and oral findings. Hence, special dental care should be given to children receiving OBTXA treatment.